Skip to main content
OpenTrials
Completed

NCT Number: NCT07712471

Multicenter Study of Thermal Radiofrequency Applied to the Musculocutaneous Nerve for the Treatment of Spasticity

This multicenter observational study evaluates the safety and effectiveness of ultrasound-guided thermal radiofrequency applied to the musculocutaneous nerve in adult patients with focal elbow flexor spasticity secondary to central nervous system injury. Hypothesis: Thermal radiofrequency treatment of the musculocutaneous nerve in patients with spasticity resulting from damage to the central nervous system is a safe and effective treatment for spasticity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Complexo Hospitalario Universitario A Coruña

A Coruña, 15006, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent.
  • Age 18 years or older.
  • Diagnosis of spasticity secondary to central nervous system injury.
  • Predominant elbow flexor spastic pattern dependent on the musculocutaneous nerve.
  • Patients with severe spasticity refractory to conservative treatments who underwent thermal radiofrequency treatment of the musculocutaneous nerve during the study period.

Exclusion criteria

  • No signed informed consent.
  • Age under 18 years.
  • Radiofrequency treatment applied to patients without central nervous system injury.
  • Absence of follow-up after radiofrequency treatment, for any reason, for a minimum period of 2 months.

Treatment and study plan

Radiofrequency

Device

Thermal Radiofrequency of the Musculocutaneous Nerve for the Treatment of Spasticity

Primary outcomes

  1. Goniometry

    Time frame: Baseline, 2 months, and 6 months after treatment

    Passive elbow range of motion assessed by goniometry. Maximum passive elbow extension is measured in degrees using a standard goniometer. Values range from -160°, indicating complete elbow flexion, to 0°, indicating complete elbow extension. Higher values (closer to 0°) indicate greater passive elbow extension and a better outcome, whereas more negative values indicate a worse outcome.

  2. Modified Ashworth Scale

    Time frame: Baseline, 2 months, and 6 months after treatment

    Elbow flexor muscle tone is assessed using the Modified Ashworth Scale, a 6-category ordinal scale with scores of 0, 1, 1+, 2, 3, and 4. The minimum score is 0, indicating no increase in muscle tone, and the maximum score is 4, indicating that the affected limb is rigid in flexion or extension. Higher scores indicate greater muscle tone and a worse outcome.

Secondary outcomes

  1. Goal Attaintment Scaling

    Time frame: 2 months, and 6 months after treatment.

    Achievement of individually predefined treatment goals is assessed using Goal Attainment Scaling, a 5-point ordinal scale ranging from -2 to +2: -2 indicates a much worse outcome than expected, -1 a somewhat worse outcome than expected, 0 the expected outcome, +1 a somewhat better outcome than expected, and +2 a much better outcome than expected. Higher scores indicate greater goal attainment and a better outcome.

  2. Visual Analog Scale

    Time frame: Baseline, 2 months, and 6 months after treatment

    Pain intensity is assessed using the Visual Analog Scale, ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable. Higher scores indicate greater pain intensity and a worse outcome.

  3. Spasticity-related Quality Of Life 6-Dimensions (SQoL-6D)

    Time frame: Baseline, 2 months, and 6 months after treatment.

    Each of the six dimensions of the Spasticity-Related Quality of Life 6-Dimensions instrument (SQoL-6D) is assessed individually over the previous 7 days using a 5-point ordinal scale ranging from 0 to 4. Higher scores indicate greater impairment and a worse outcome.

  4. Physician Global Assessment (PGA)

    Time frame: Baseline, 2 months, and 6 months after treatment.

    Overall response to treatment is assessed by the physician using a 9-point ordinal scale ranging from -4 to +4: -4 indicates markedly worse, -3 much worse, -2 worse, -1 slightly worse, 0 no change, +1 slightly improved, +2 improved, +3 much improved, and +4 markedly improved. Higher scores indicate greater improvement and a better outcome.

  5. Patient Global Impression of Change (PGI-C)

    Time frame: Baseline, 2 months, and 6 months after treatment

    The patient's overall perception of change following treatment is assessed using the Patient Global Impression of Change (PGI-C), a 7-point ordinal scale ranging from -3 to +3: -3 indicates very much worse, -2 much worse, -1 minimally worse, 0 no change, +1 minimally improved, +2 much improved, and +3 very much improved. Higher scores indicate greater improvement and a better outcome.

Sponsors and collaborators

Lead sponsor

Fundación Pública Galega de Investigación Biomédica INIBIC

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 17, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.